Do analysts recommend NERV or RYM?

Minerva Neurosciences presently has a consensus target price of $10.33, indicating a potential upside of 196.08%. Given Minerva Neurosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Minerva Neurosciences is more favorable than RYTHM. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Minerva Neurosciences 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75 RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend ACOG or RYM?

Alpha Cognition presently has a consensus price target of $18.00, indicating a potential upside of 105.01%. Given Alpha Cognition's stronger consensus rating and higher possible upside, equities research analysts clearly believe Alpha Cognition is more favorable than RYTHM. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alpha Cognition 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ACOG or RYM more profitable?

RYTHM has a net margin of -6.20% compared to Alpha Cognition's net margin of -153.61%. RYTHM's return on equity of -12.57% beat Alpha Cognition's return on equity. Company Net Margins Return on Equity Return on Assets Alpha Cognition -153.61% -54.60% -43.47% RYTHM -6.20% -12.57% -2.60%

Does the media prefer ACOG or RYM?

In the previous week, RYTHM had 3 more articles in the media than Alpha Cognition. MarketBeat recorded 4 mentions for RYTHM and 1 mentions for Alpha Cognition. Alpha Cognition's average media sentiment score of 0.42 beat RYTHM's score of -0.24 indicating that Alpha Cognition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Cognition 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral RYTHM 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend RYM or NMRA?

Neumora Therapeutics has a consensus target price of $6.57, suggesting a potential upside of 798.60%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Neumora Therapeutics is more favorable than RYTHM. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Neumora Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78

Does the media refer more to RYM or NMRA?

In the previous week, RYTHM had 2 more articles in the media than Neumora Therapeutics. MarketBeat recorded 4 mentions for RYTHM and 2 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 0.67 beat RYTHM's score of -0.24 indicating that Neumora Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RYTHM 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Neumora Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate RYM or SLGL?

Sol-Gel Technologies has a consensus target price of $197.50, suggesting a potential upside of 230.77%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Sol-Gel Technologies is more favorable than RYTHM. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sol-Gel Technologies 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67

Is RYM or SLGL more profitable?

RYTHM has a net margin of -6.20% compared to Sol-Gel Technologies' net margin of -910.14%. RYTHM's return on equity of -12.57% beat Sol-Gel Technologies' return on equity. Company Net Margins Return on Equity Return on Assets RYTHM -6.20% -12.57% -2.60% Sol-Gel Technologies -910.14% -44.05% -36.96%

Does the media favor RYM or SLGL?

In the previous week, RYTHM had 2 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 4 mentions for RYTHM and 2 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 0.45 beat RYTHM's score of -0.24 indicating that Sol-Gel Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RYTHM 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Sol-Gel Technologies 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer RYM or LFCR?

Lifecore Biomedical has a consensus price target of $6.50, indicating a potential upside of 47.73%. Given Lifecore Biomedical's stronger consensus rating and higher possible upside, analysts clearly believe Lifecore Biomedical is more favorable than RYTHM. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lifecore Biomedical 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor RYM or LFCR?

In the previous week, RYTHM had 3 more articles in the media than Lifecore Biomedical. MarketBeat recorded 4 mentions for RYTHM and 1 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.00 beat RYTHM's score of -0.24 indicating that Lifecore Biomedical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RYTHM 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Lifecore Biomedical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

RYTHM (RYM) Competitors

$23.01 -0.46 (-1.96%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$22.98 -0.03 (-0.13%)

As of 09/23/2026 07:30 PM Eastern

Compare

RYM vs. NERV, ACOG, NMRA, SLGL, and LFCR

Should you buy RYTHM stock or one of its competitors? RYTHM's main competitors and comparable companies include Minerva Neurosciences (NERV), Alpha Cognition (ACOG), Neumora Therapeutics (NMRA), Sol-Gel Technologies (SLGL), and Lifecore Biomedical (LFCR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does RYTHM compare to Minerva Neurosciences?

Minerva Neurosciences (NASDAQ:NERV) and RYTHM (NASDAQ:RYM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

RYTHM has higher revenue and earnings than Minerva Neurosciences. RYTHM is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A
RYTHM	$51.01M	0.98	-$33.26M	-$10.53	N/A

In the previous week, RYTHM had 4 more articles in the media than Minerva Neurosciences. MarketBeat recorded 4 mentions for RYTHM and 0 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.05 beat RYTHM's score of -0.24 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Minerva Neurosciences	Positive
RYTHM	Neutral

Minerva Neurosciences has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. Minerva Neurosciences' return on equity of 0.00% beat RYTHM's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-31.72%
RYTHM	-6.20%	-12.57%	-2.60%

Minerva Neurosciences has a beta of -0.08, meaning that its stock price is 108% less volatile than the broader market. Comparatively, RYTHM has a beta of 9.44, meaning that its stock price is 844% more volatile than the broader market.

Minerva Neurosciences presently has a consensus target price of $10.33, indicating a potential upside of 196.08%. Given Minerva Neurosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Minerva Neurosciences is more favorable than RYTHM.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 6.0% of RYTHM shares are held by institutional investors. 1.7% of Minerva Neurosciences shares are held by company insiders. Comparatively, 3.5% of RYTHM shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Minerva Neurosciences beats RYTHM on 8 of the 15 factors compared between the two stocks.

How does RYTHM compare to Alpha Cognition?

Alpha Cognition (NASDAQ:ACOG) and RYTHM (NASDAQ:RYM) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

6.0% of RYTHM shares are owned by institutional investors. 8.6% of Alpha Cognition shares are owned by insiders. Comparatively, 3.5% of RYTHM shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Alpha Cognition has a beta of 2.32, indicating that its stock price is 132% more volatile than the broader market. Comparatively, RYTHM has a beta of 9.44, indicating that its stock price is 844% more volatile than the broader market.

Alpha Cognition presently has a consensus price target of $18.00, indicating a potential upside of 105.01%. Given Alpha Cognition's stronger consensus rating and higher possible upside, equities research analysts clearly believe Alpha Cognition is more favorable than RYTHM.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, RYTHM had 3 more articles in the media than Alpha Cognition. MarketBeat recorded 4 mentions for RYTHM and 1 mentions for Alpha Cognition. Alpha Cognition's average media sentiment score of 0.42 beat RYTHM's score of -0.24 indicating that Alpha Cognition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Cognition	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
RYTHM	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

RYTHM has a net margin of -6.20% compared to Alpha Cognition's net margin of -153.61%. RYTHM's return on equity of -12.57% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-153.61%	-54.60%	-43.47%
RYTHM	-6.20%	-12.57%	-2.60%

Alpha Cognition has higher earnings, but lower revenue than RYTHM. Alpha Cognition is trading at a lower price-to-earnings ratio than RYTHM, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.22M	18.71	-$20.67M	-$1.10	N/A
RYTHM	$51.01M	0.98	-$33.26M	-$10.53	N/A

Summary

Alpha Cognition and RYTHM tied by winning 8 of the 16 factors compared between the two stocks.

How does RYTHM compare to Neumora Therapeutics?

RYTHM (NASDAQ:RYM) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

In the previous week, RYTHM had 2 more articles in the media than Neumora Therapeutics. MarketBeat recorded 4 mentions for RYTHM and 2 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 0.67 beat RYTHM's score of -0.24 indicating that Neumora Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RYTHM	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neumora Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

6.0% of RYTHM shares are owned by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are owned by institutional investors. 3.5% of RYTHM shares are owned by insiders. Comparatively, 26.9% of Neumora Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Neumora Therapeutics has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. RYTHM's return on equity of -12.57% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RYTHM	-6.20%	-12.57%	-2.60%
Neumora Therapeutics	N/A	-242.28%	-131.32%

Neumora Therapeutics has a consensus target price of $6.57, suggesting a potential upside of 798.60%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Neumora Therapeutics is more favorable than RYTHM.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Neumora Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

RYTHM has a beta of 9.44, meaning that its share price is 844% more volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.71, meaning that its share price is 171% more volatile than the broader market.

RYTHM has higher revenue and earnings than Neumora Therapeutics. RYTHM is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYTHM	$51.01M	0.98	-$33.26M	-$10.53	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A

Summary

Neumora Therapeutics beats RYTHM on 10 of the 16 factors compared between the two stocks.

How does RYTHM compare to Sol-Gel Technologies?

RYTHM (NASDAQ:RYM) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

RYTHM has a net margin of -6.20% compared to Sol-Gel Technologies' net margin of -910.14%. RYTHM's return on equity of -12.57% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RYTHM	-6.20%	-12.57%	-2.60%
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%

Sol-Gel Technologies has lower revenue, but higher earnings than RYTHM. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than RYTHM, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYTHM	$51.01M	0.98	-$33.26M	-$10.53	N/A
Sol-Gel Technologies	$19.39M	8.65	-$6.13M	-$5.64	N/A

RYTHM has a beta of 9.44, indicating that its stock price is 844% more volatile than the broader market. Comparatively, Sol-Gel Technologies has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

In the previous week, RYTHM had 2 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 4 mentions for RYTHM and 2 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 0.45 beat RYTHM's score of -0.24 indicating that Sol-Gel Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RYTHM	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sol-Gel Technologies	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

6.0% of RYTHM shares are owned by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are owned by institutional investors. 3.5% of RYTHM shares are owned by insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Sol-Gel Technologies has a consensus target price of $197.50, suggesting a potential upside of 230.77%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Sol-Gel Technologies is more favorable than RYTHM.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Sol-Gel Technologies beats RYTHM on 10 of the 17 factors compared between the two stocks.

How does RYTHM compare to Lifecore Biomedical?

RYTHM (NASDAQ:RYM) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

RYTHM has a net margin of -6.20% compared to Lifecore Biomedical's net margin of -29.93%. Lifecore Biomedical's return on equity of 0.00% beat RYTHM's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RYTHM	-6.20%	-12.57%	-2.60%
Lifecore Biomedical	-29.93%	N/A	-16.16%

6.0% of RYTHM shares are owned by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are owned by institutional investors. 3.5% of RYTHM shares are owned by company insiders. Comparatively, 32.7% of Lifecore Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

RYTHM has a beta of 9.44, suggesting that its share price is 844% more volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

In the previous week, RYTHM had 3 more articles in the media than Lifecore Biomedical. MarketBeat recorded 4 mentions for RYTHM and 1 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.00 beat RYTHM's score of -0.24 indicating that Lifecore Biomedical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RYTHM	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lifecore Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lifecore Biomedical has a consensus price target of $6.50, indicating a potential upside of 47.73%. Given Lifecore Biomedical's stronger consensus rating and higher possible upside, analysts clearly believe Lifecore Biomedical is more favorable than RYTHM.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lifecore Biomedical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

RYTHM has higher earnings, but lower revenue than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than RYTHM, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYTHM	$51.01M	0.98	-$33.26M	-$10.53	N/A
Lifecore Biomedical	$128.87M	1.29	-$40.50M	-$1.07	N/A

Summary

Lifecore Biomedical beats RYTHM on 10 of the 16 factors compared between the two stocks.

Get RYTHM News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RYM vs. The Competition

Export

Metric	RYTHM	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$50.14M	$12.60B	$7.31B	$13.29B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	-2.19	792.28	274.08	25.69
Price / Sales	0.98	862.22	638.21	78.99
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	3.80	10.59	10.47	6.32
Net Income	-$33.26M	$2.81B	$3.49B	$359.73M
7 Day Performance	2.33%	-0.11%	-0.67%	0.17%
1 Month Performance	0.07%	-1.34%	-3.17%	-3.27%
1 Year Performance	-38.97%	2.86%	15.14%	5.58%

RYTHM Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RYM RYTHM	0.6329 of 5 stars	$23.01 -2.0%	N/A	-39.2%	$50.14M	$51.01M	N/A	141	News Coverage
NERV Minerva Neurosciences	2.2383 of 5 stars	$3.83 -4.5%	$10.33 +169.8%	+65.0%	$191.47M	N/A	N/A	7	Positive News Analyst Forecast
ACOG Alpha Cognition	3.7054 of 5 stars	$8.80 +1.0%	$18.00 +104.5%	+7.1%	$189.68M	$10.22M	N/A	71	Positive News
NMRA Neumora Therapeutics	2.4487 of 5 stars	$0.83 -16.8%	$6.57 +690.5%	-61.7%	$187.78M	N/A	N/A	63	News Coverage High Trading Volume
SLGL Sol-Gel Technologies	3.1596 of 5 stars	$64.40 -1.2%	$197.50 +206.7%	+104.8%	$183.15M	$19.39M	N/A	28

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RYM) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

RYTHM (RYM) Competitors

RYM vs. NERV, ACOG, NMRA, SLGL, and LFCR

How does RYTHM compare to Minerva Neurosciences?

Summary

How does RYTHM compare to Alpha Cognition?

Summary

How does RYTHM compare to Neumora Therapeutics?

Summary

How does RYTHM compare to Sol-Gel Technologies?

Summary

How does RYTHM compare to Lifecore Biomedical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RYM vs. The Competition

RYTHM Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

RYTHM (RYM) Competitors

RYM vs. NERV, ACOG, NMRA, SLGL, and LFCR

How does RYTHM compare to Minerva Neurosciences?

Which has higher earnings & valuation, NERV or RYM?

Does the media favor NERV or RYM?

Is NERV or RYM more profitable?

Which has more volatility and risk, NERV or RYM?

Do analysts recommend NERV or RYM?

Do insiders & institutionals have more ownership in NERV or RYM?

Summary

How does RYTHM compare to Alpha Cognition?

Do insiders and institutionals believe in ACOG or RYM?

Which has more volatility & risk, ACOG or RYM?

Do analysts recommend ACOG or RYM?

Does the media prefer ACOG or RYM?

Is ACOG or RYM more profitable?

Which has better valuation & earnings, ACOG or RYM?

Summary

How does RYTHM compare to Neumora Therapeutics?

Does the media refer more to RYM or NMRA?

Do insiders & institutionals hold more shares of RYM or NMRA?

Is RYM or NMRA more profitable?

Do analysts recommend RYM or NMRA?

Which has more risk and volatility, RYM or NMRA?

Which has better valuation & earnings, RYM or NMRA?

Summary

How does RYTHM compare to Sol-Gel Technologies?

Is RYM or SLGL more profitable?

Which has preferable earnings and valuation, RYM or SLGL?

Which has more volatility & risk, RYM or SLGL?

Does the media favor RYM or SLGL?

Do institutionals and insiders hold more shares of RYM or SLGL?

Do analysts rate RYM or SLGL?

Summary

How does RYTHM compare to Lifecore Biomedical?

Is RYM or LFCR more profitable?

Do insiders & institutionals believe in RYM or LFCR?

Which has more volatility & risk, RYM or LFCR?

Does the media favor RYM or LFCR?

Do analysts prefer RYM or LFCR?

Which has stronger earnings & valuation, RYM or LFCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RYM vs. The Competition

RYTHM Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools